Method for the Selection of Serum Biomarkers of Epigenetic Alterations, Particularly of Global Hypomethylation and Their Uses
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Apr 16, 2015
app pub date -
Apr 17, 2013
filing date -
Apr 17, 2012
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention provides a novel method for the selection of serum biomarkers of epigenetic alterations, particularly of global hypomethylation, and the use of said biomarkers in a method for screening, diagnosing and following a pathology associated to epigenetic alterations of cell in an individual, such as placental-related pathology or cancer. The present invention also relates to a method of detecting a predisposition to placental-related pathology or cancer based on the presence or the level of said biomarker in a serum or plasma sample of said patient. The present invention also relates to a method for predicting and following the effect of drugs targeting epigenetic modifications and in particular the effect of demethylating agents. The present invention is directed to a kit comprising such serum biomarkers of epigenetic alterations, particularly of global hypomethylation.
First Claim
Other Claims data not available